View : 349 Download: 0

Full metadata record

DC Field Value Language
dc.contributor.author김이준-
dc.date.accessioned2022-02-21T16:30:08Z-
dc.date.available2022-02-21T16:30:08Z-
dc.date.issued2022-
dc.identifier.issn2045-7022-
dc.identifier.otherOAK-30934-
dc.identifier.urihttps://dspace.ewha.ac.kr/handle/2015.oak/260510-
dc.description.abstractBackground: Several type B adverse drug reactions (ADRs), especially severe cutaneous adverse reactions (SCARs), are associated with particular human leukocyte antigen (HLA) genotypes. However, pre-stored HLA information obtained from other clinical workups has not been used to prevent ADRs. We aimed to simulate the preemptive use of pre-stored HLA information in electronic medical records to evaluate whether this information can prevent ADRs. Methods: We analyzed the incidence and the risk of ADRs for selected HLA alleles (HLA-B*57:01, HLA-B*58:01, HLA-A*31:01, HLA-B*15:02, HLA-B*15:11, HLA-B*13:01, HLA-B*59:01, and HLA-A*32:01) and seven drugs (abacavir, allopurinol, carbamazepine, oxcarbazepine, dapsone, methazolamide, and vancomycin) using pre-stored HLA information of transplant patients based on the Pharmacogenomics Knowledge Base guidelines and experts' consensus. Results: Among 11,988 HLA-tested transplant patients, 4092 (34.1%) had high-risk HLA alleles, 4583 (38.2%) were prescribed risk drugs, and 580 (4.8%) experienced type B ADRs. Patients with HLA-B*58:01 had a significantly higher incidence of type B ADR and SCARs associated with allopurinol use than that of patients without HLA-B*58:01 (17.2% vs. 11.9%, odds ratio [OR] 1.53 [95% confidence interval {CI} 1.09–2.13], p = 0.001, 2.3% versus 0.3%, OR 7.13 [95% CI 2.19–22.69], p < 0.001). Higher risks of type B ADR and SCARs were observed in patients taking carbamazepine or oxcarbazepine if they had one of HLA-A*31:01, HLA-B*15:02, or HLA-B*15:11 alleles. Vancomycin and dapsone use in HLA-A*32:01 and HLA-B*13:01 carriers, respectively, showed trends toward increased risk of type B ADRs. Conclusion: Utilization of pre-stored HLA data can prevent type B ADRs including SCARs by screening high-risk patients. © 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.-
dc.languageEnglish-
dc.publisherJohn Wiley and Sons Inc-
dc.subjecthumanes leukozytenantigen-
dc.subjectpharmakogenomik-
dc.subjectpräventive genotypisierung-
dc.subjectuberempfindlichkeit-
dc.subjectunerwünschte arzneimittelwirkung-
dc.titleReducing severe cutaneous adverse and type B adverse drug reactions using pre-stored human leukocyte antigen genotypes-
dc.typeArticle-
dc.relation.issue1-
dc.relation.volume12-
dc.relation.indexSCIE-
dc.relation.indexSCOPUS-
dc.relation.journaltitleClinical and Translational Allergy-
dc.identifier.doi10.1002/clt2.12098-
dc.identifier.wosidWOS:000747683100005-
dc.identifier.scopusid2-s2.0-85123752678-
dc.author.googleLee K.H.-
dc.author.googleKang D.Y.-
dc.author.googleKim H.H.-
dc.author.googleKim Y.J.-
dc.author.googleKim H.J.-
dc.author.googleKim J.H.-
dc.author.googleSong E.Y.-
dc.author.googleYun J.-
dc.author.googleKang H.-R.-
dc.contributor.scopusid김이준(56714252700)-
dc.date.modifydate20230118115726-
Appears in Collections:
의료원 > 의료원 > Journal papers
Files in This Item:
There are no files associated with this item.
Export
RIS (EndNote)
XLS (Excel)
XML


qrcode

BROWSE